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ABSTRACT
Cathelicidins are CHDP with essential roles in innate
host defense but also more recently associated with
the pathogenesis of certain chronic diseases. These
peptides have microbicidal potential and the capacity
to modulate innate immunity and inflammatory pro-
cesses. PMN are key innate immune effector cells with
pivotal roles in defense against infection. The appropri-
ate regulation of PMN function, death, and clearance is
critical to innate immunity, and dysregulation is impli-
cated in disease pathogenesis. The efferocytosis of ap-
optotic PMN, in contrast to necrotic cells, is proposed
to promote the resolution of inflammation. We demon-
strate that the human cathelicidin LL-37 induced rapid
secondary necrosis of apoptotic human PMN and iden-
tify an essential minimal region of LL-37 required for
this activity. Using these LL-37-induced secondary ne-
crotic PMN, we characterize the consequence for
macrophage inflammatory responses. LL-37-induced
secondary necrosis did not inhibit PMN ingestion by
monocyte-derived macrophages and in contrast to
expectation, was not proinflammatory. Furthermore,
the anti-inflammatory effects of apoptotic PMN on acti-
vated macrophages were retained and even potenti-
ated after LL-37-induced secondary necrosis. How-
ever, this process of secondary necrosis did induce the
release of potentially harmful PMN granule contents.
Thus, we suggest that LL-37 can be a potent inducer of
PMN secondary necrosis during inflammation without
promoting macrophage inflammation but may mediate
host damage through PMN granule content release un-
der chronic or dysregulated conditions. J. Leukoc. Biol.
86: 891–902; 2009.
Introduction
PMN are important first-line innate immune cells, which are
mobilized rapidly in response to infection and injury. How-
ever, the arsenal of products used by PMN to destroy microbes
is also potentially deleterious to host cells. Appropriate regula-
tion of PMN influx, activation, death, and removal is therefore
critical, and dysregulation of these processes has been impli-
cated in the pathogenesis of chronic lung diseases [1, 2].
PMN have a short half-life and undergo spontaneous apop-
tosis. This programmed and regulated form of cell death en-
ables recognition, ingestion, and removal by macrophages or
DCs, a process involving multiple receptors and adaptors [3].
Efferocytosis (the uptake of apoptotic cells) can protect the
host from the release of toxic PMN intracellular contents and
induce anti-inflammatory and immunosuppressive effects.
These include dampening the LPS-induced, proinflammatory
cytokine response and enhancing anti-inflammatory responses
by macrophages [4–6]. These processes, in addition to an ac-
tive switch in the lipid mediators generated to the production
of lipoxins, resolvins, and protectins [7], can stimulate the res-
olution of inflammation. However, in the absence of efferocy-
tosis, apoptotic PMN will undergo secondary necrosis with loss
of membrane integrity. Although necrosis is typically regarded
as proinflammatory [1], the effect of PMN secondary necrosis
on inflammation and the mechanisms of clearance of these
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cells are relatively poorly understood. Further understanding
of these issues is of great significance to evaluate the impact of
delayed PMN clearance in the resolution of inflammation.
The survival and death of PMN can be modulated signifi-
cantly by the inflammatory milieu, including cytokines such as
TNF- and GM-CSF, TLR agonists (e.g., LPS), and bacterial
products (e.g., pyocyanin) [8], in addition to potential thera-
peutic modulators [9]. The human CHDP (also known as anti-
microbial peptide) LL-37 can also modulate PMN death pathways
in vitro [10, 11]. We have demonstrated that LL-37 promotes
PMN necrosis at the expense of apoptosis [10]. However, the
mechanisms involved and the consequences for inflammation
remain to be determined.
CHDP are key evolutionarily conserved components of in-
nate host defense systems, which are being modified and de-
veloped as novel, antimicrobial therapeutic agents. The two
major CHDP families in vertebrates are defensins and catheli-
cidins. LL-37 is the predominant, mature cationic peptide frag-
ment of the sole human cathelicidin hCAP-18, which is found
at high concentration in neutrophil specific granules and is
cleaved to its active form by proteinase-3 [12, 13]. LL-37 is also
produced by epithelial cells from a variety of tissues in re-
sponse to infectious and inflammatory stimuli and is expressed
by macrophages and other leukocytes [14]. In addition to di-
rect microbicidal potential, LL-37 has a broad range of immu-
nomodulatory functions including antiendotoxic activity and
chemotactic function, modulation of chemokine and cytokine
responses, promotion of cell wound-healing and angiogenesis,
modulation of DC differentiation and function, and the capac-
ity to modulate cell death pathways [10, 11, 15–27]. In vivo
evidence in humans and mice supports a critical role in innate
defense [28–31], hCAP-18/LL-37 concentration in BALF is
increased significantly in human lung infections [32], and
overexpression of LL-37 in the murine lung enhanced the
clearance of infection [33]. However, increased levels of
hCAP-18/LL-37 have also been associated with and implicated
in chronic disease processes [34–36]. Thus, despite a funda-
mental role in innate defense, dysregulated control of LL-37
may be detrimental to the host. The key immunomodulatory
properties that contribute to the physiological role of LL-37 in
host defense and how these might contribute to disease patho-
genesis when dysregulated remain unresolved.
We hypothesized that LL-37-induced necrosis of PMN could
alter efferocytosis and the nature of the subsequent inflamma-
tory response and could lead to the release of potentially dam-
aging PMN intracellular contents. To examine the role of LL-
37-induced PMN necrosis on the inflammatory response, we
characterized the dynamics of LL-37-induced PMN necrosis
before evaluating the effect of LL-37-induced PMN necrosis on
efferocytosis and macrophage inflammatory responses and the
consequences for release of PMN intracellular contents.
MATERIALS AND METHODS
Reagents
rhGM-CSF was purchased from Research Diagnostics Inc. (Flanders, NJ,
USA). R-Roscovitine was supplied by A. G. Scientific (San Diego, CA,
USA). Ultra-pure LPS from the Escherichia coli 0111:B4 strain was pur-
chased from InvivoGen (San Diego, CA, USA). Dexamethasone was pur-
chased from Organon Laboratories Ltd. (Cambridge, UK). rhCD40L
and IFN- were purchased from PeproTech ED Ltd. (London, UK).
LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) and
mCRAMP (GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ) were syn-
thesized by N-(9-fluorenyl) methoxycarbonyl chemistry at the Nucleic
Acid/Protein Service Unit at the University of British Columbia (Canada), as
described previously [10]. Peptides were purified by reverse-phase HPLC and
were at least 98% pure. The concentration of the peptides in solution was de-
termined by amino acid analysis. Scrambled LL-37 (RSLEGTDRFPFVRLKN-
SRKLEFKDIKGIKREQFVKIL) was purchased from CSS-Albachem Ltd. (Glads-
muir, Scotland, UK), and the panel of 16 overlapping 22-mer partial LL-37
peptides (from N-terminal peptide LLGDFFRKSKEKIGKEFKRIVQ through to
C-terminal peptide EFKRIVQRIKDFLRNLVPRTES) was synthesized by Jan W.
Drijfhout at Leiden University Medical Center (The Netherlands) as described
previously [37]. Peptides were dissolved in endotoxin-free water (Sigma-Al-
drich, Poole, UK) and stored at –20°C until further use. All reagents were
tested using a LAL kinetic-quantitative chromogenic LAL assay (Cambrex,
Walkersville, MD, USA) to ensure they were free of endotoxin and reconsti-
tuted in endotoxin-free water.
Isolation of human blood neutrophils
Human venous blood was collected according to Lothian Research Ethics
Committee approval #08/S1103/38 or #1702/95/4/72 using sodium citrate
anticoagulant (Phoenix Pharma Ltd., Gloucester, UK), and cells were sepa-
rated by Dextran sedimentation, followed by discontinuous, isotonic Percoll
gradient centrifugation as described previously [10]. Granulocytes were
washed in PBS without calcium or magnesium (PAA Laboratories, Somer-
set, UK) and resuspended in IMDM (PAA Laboratories) with 10% FCS
(Biosera, East Sussex, UK). Purity was assessed by morphological criteria
using cytocentrifuge preparations and FACS analyses and antibodies against
human CD16 (Caltag-Medsystems Ltd., Towcester, UK) and CD66b (BD
Biosciences, San Diego, CA, USA) to distinguish PMN from eosinophils
and against CD14, CD4, CD8, and CD19 (Caltag-Medsystems Ltd.). Granu-
locyte purity of 98% was yielded by this method, and granulocytes were
typically 95–98% PMN. However, high eosinophil donors were also studied,
demonstrating no significant effect of eosinophil number on LL-37-induced
secondary necrosis of apoptotic PMN. Total cell number was assessed by
hemacytometer counts and by NucleoCounter YC-100 (ChemoMetec,
Allerød, Denmark) automated cell number counting.
Assessment of PMN death
Freshly isolated PMN were incubated at 37°C, 5% CO2, at 5  10
6/ml in IMDM
with 10% (v/v) FCS in the presence of LL-37, GM-CSF, R-Roscovitine, LPS,
mCRAMP, scrambled LL-37, or partial LL-37 peptides at the stated concentrations
or in control media in triplicate over the time periods detailed. To induce primary
necrosis, freshly isolated cells were heated at 65°C for 30 min. Cell death was as-
sessed by light microscopic evaluation of apoptotic morphology as described [10]
and also by examining cells stained at 4°C with FITC-labeled AV (Roche Applied
Sciences, West Sussex, UK), diluted 1:2000 in HBSS with 5 mM CaCl2, and 3
g/ml PI (Invitrogen Ltd., Paisley, UK) for flow cytometric evaluation using a
FACSCalibur, counting 10,000 cells, and analyzed using FloJo software (TreeStar
Inc., Ashland, OR, USA). High concentrations of LL-37 can lead to a complete
loss of cells from analysis [10, 38]. To evaluate this accurately, the concentration-
dependent induction of necrosis was determined by FACS, and the total detect-
able PMN numbers were determined using a NucleoCounter YC-100 (Chemo-
Metec) after 20 h culture over a range of LL-37 concentrations (25 g/ml). An
approximate EC50  3.8 g/ml was determined for LL-37-induced necrosis, and
LL-37 10 g/ml (2 M) was found to induce a significant and concentration-
dependent loss in total detectable cell number (total cell number as a proportion
of control sample81%5% at 20 h, LL-37 10 g/ml; P0.01; n20). In con-
trast, incubation with 5 g/ml LL-37 did not result in a significant decrease,
although a degree of cell loss was observed sometimes. LL-37 was therefore used
at 5 g/ml for further studies examining LL-37-mediated modulation of PMN
cell death.
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TEM
Freshly isolated PMN were incubated with or without 5 g/ml LL-37 for
20 h, as described above, centrifuged at 250 g for 5 min at room tempera-
ture, and resuspended gently in 1 ml 2.5% glutaraldehyde (Sigma-Aldrich)
in 0.1 M sodium cacodylate buffer, pH 7.3 (Sigma-Aldrich), for 1 h. Cells
were washed in three 10-min changes of 0.1 M sodium cacodylate and post-
fixed in 1% osmium tetroxide in 0.1 M sodium cacodylate for 45 min be-
fore three 10-min changes of 0.1 M sodium cacodylate. Samples were then
dehydrated in 50%, 70%, 90%, and 100% normal grade acetones before
two 10-min changes in analar acetone and embedded in Araldite resin. To-
luidine blue-stained sections (1 m) were previewed before 60 nm ultra-
thin sections were cut from selected areas, stained in uranyl acetate and
lead citrate, and then viewed in a Philips CM120 transmission electron mi-
croscope (FEI UK Ltd., Cambridge, UK). Images were taken on a Gatan
Orius charged-coupled device camera (Gatan UK, Oxon, UK).
Western immunoblotting
Freshly isolated PMN were incubated as described above over a range of
LL-37 concentrations. At Time 0 h or after 20 h, cells were washed with
PBS without Ca2 and Mg2, and proteins were extracted using Mamma-
lian Protein Extraction Reagent (Pierce/Perbio Science UK, Cheshire, UK)
containing 30 l/ml HaltTM protease inhibitor cocktail, 30 l/ml HaltTM
phosphatase inhibitor cocktail, 10 l/ml EDTA solution (all Pierce/Perbio
Science UK), 30 M pepstatin (Sigma-Aldrich), and 10 M lactacystin (Cal-
biochem/Merck Biosciences Ltd., Nottingham, UK). Total protein concen-
trations were determined by bicinchoninic acid assay (Pierce/Perbio Sci-
ence UK). Equivalent total protein (20–50 g) was resolved in Pierce
Precise gels (Pierce/Perbio Science UK) transferred to Immun-Blot
polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules,
CA, USA) and immunoblotting performed as described [10] with anti-hu-
man cleaved caspase-3 rabbit polyclonal antibody and reprobed with anti-
pan-actin antibody (both Cell Signaling Technology, Beverly, MA, USA) for
protein loading correction via densitometric analysis using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
Phagocytic studies
Human PBMC were isolated by isotonic Percoll gradient centrifugation as
described above and incubated at 4 106/ml in IMDM at 37°C, 5% CO2,
for 1 h. Nonadherent cells were removed and adherent monocytes cul-
tured for 5–7 days in IMDM and 10% autologous serum to generate MDM.
For light microscopic analyses of phagocytosis, PMN were incubated previ-
ously for 20 h, with or without LL-37 (or scrambled LL-37) at the stated
concentrations (as described above), and the level of apoptosis was assessed
as described. PMN (2.5106; 2.5:1 ratio of PMN:MDM) were overlaid
onto HBSS-washed MDM monolayers for 1 h at 37°C. MDM were then
washed gently four times with IMDM to remove noningested PMN and
fixed with 2.5% paraformaldehyde (Sigma-Aldrich) for 10 min. PMN MPO
was stained with 0.1 mg/ml dimethoxybenzidine (Sigma-Aldrich) and
0.03% (v/v) H2O2 (Sigma-Aldrich) before analysis by light microscopy,
counting at least 200 MDM in five randomly selected fields of view to evalu-
ate the proportion of MDM-containing peroxidase-positive cells, with n  2
replicates/experiment. Only MDM that had engulfed PMN clearly were
scored as positive. For flow cytometric analyses of phagocytosis, freshly iso-
lated PMN were stained with Cell Tracker Green (Molecular Probes, Eugene,
OR, USA) at 37°C for 20 min, according to the manufacturer’s instructions,
and then washed twice with PBS before incubation for 20 h in the presence or
absence of LL-37, as described. The effects of LL-37 were not altered by Cell
Tracker Green staining (data not shown). MDM were exposed to PMN as
described above, but after 1 h incubation, cells were detached and col-
lected using 0.05% trypsin/0.02% EDTA solution (Cambrex). Samples were
analyzed by FACSCalibur as described previously [39], with n  2 repli-
cates/experiment. The number of Cell Tracker Green-positive events in the
macrophage gate (based on forward- and side-scatter) represented the
number of macrophages that had ingested PMN and was evaluated as a
proportion of total number of MDM. As a positive control, wells of adher-
ent monocytes were also cultured in the presence of 1 M dexamethasone
for 5 days, a process demonstrated previously to up-regulate MDM phagocy-
tosis of dead PMN [40].
MDM cytokine production
Freshly isolated PMN at 5  106/ml were incubated for 20 h in the pres-
ence or absence of LL-37, scrambled LL-37, or partial LL-37 peptides p1
(LLGDFFRKSKEKIGKEFKRIVQ), p2 (KIGKEFKRIVQRIKDFLRNLVP), or
p3 (EFKRIVQRIKDFLRNLVPRTES) at the concentrations indicated in 10%
FCS as described above. Samples (1 ml) were collected and each split in
two, and half of each sample was centrifuged at 230 g before collection of
the supernatant and resuspension of the cells in 0.5 ml X-vivo 10 media
(Lonza Biologics, Slough, UK), with or without 10% FCS. Washed MDM,
with or without concomitant exposure to 10 ng/ml E. coli 0111:B4 LPS or 3
g/ml rhCD40L/5 ng/ml rhIFN-, were then incubated at 37°C, 5% CO2,
for 18 h with 0.5 ml PMN in fresh X-vivo 10, PMN in the original IMDM
with 10% FCS, IMDM with 10% FCS supernatant collected from overnight-
incubated PMN, or media alone. MDM alone and PMN alone in the pres-
ence of absence of LPS and/or LL-37 were also studied as controls. Super-
natants were collected, centrifuged at 230 g for 6 min to remove cells and
particulate debris, and then stored in aliquots at –70°C. The concentrations
of TNF-, IL-6, IL-10, IL-12p70, and IL-1 in the supernatants were mea-
sured using BD Cytometric Bead Array human inflammation kits with a BD
FACSArray (BD Biosciences) or Human TNF- DuoSet ELISA (R&D Sys-
tems, Minneapolis, MN, USA), according to the manufacturer’s instruc-
tions.
MPO release
Freshly isolated PMN were incubated with different concentrations of
LL-37 or scrambled peptide for 20 h as described above, centrifuged at 230
g for 6 min, and placed immediately on ice, and the supernatants were col-
lected. To detect MPO, 100 l supernatant samples (used neat or diluted
in PBS) were incubated in the dark for 20 min at room temperature with
100 l substrate solution (1:1 mixture of H2O2 and tetramethylbenzidine;
R&D Systems), followed by addition of 50 l 2 N H2SO4 stop solution and
colorimetric analyses at 450 nm using a microplate reader. The concentra-
tion of MPO in the supernatants was evaluated as a percentage of MPO
release after complete lysis of fresh control PMN using 0.1% Triton X-100
(Sigma-Aldrich).
Statistical analysis
GraphPad Prism 5 statistical software was used to determine statistical sig-
nificance. One-way or two-way ANOVA with Bonferroni’s multiple compari-
son post-tests or Student’s t-tests was performed as appropriate. P  0.05
was considered significant. Values are expressed as mean  sem.
RESULTS
LL-37 induces the rapid secondary necrosis of
apoptotic PMN
We and others [10, 11] have demonstrated that the propor-
tion of apoptotic (AVPI–) cells detected in an in vitro model
of spontaneous apoptosis of human PMN was decreased signif-
icantly when cells were cultured with LL-37. The most prom-
inent consequence of this was an increased proportion of
necrotic (AVPI) PMN [10]. To carefully characterize LL-
37-induced, necrotic PMN, with which to examine the conse-
quences for macrophage inflammatory responses, a large donor
pool (n28 different donors) was evaluated. This demonstrated
the concentration-dependent capacity of LL-37 to promote PMN
necrosis significantly at the expense of apoptosis, with no signifi-
Li et al. LL-37-induced secondary necrosis of PMN
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cant impact on the proportion of live (AV–PI–) cells at 5
g/ml LL-37 using FACS (Fig. 1A) and morphological analy-
ses. LL-37-induced necrotic PMN were observed to be similar
to “late apoptotic” cells observed in control samples at 20 h,
with less-severe loss of membrane integrity than primary necro-
sis induced by heat treatment of cells (Fig. 1B). TEM was used
to confirm the capacity of LL-37 to promote PMN necrosis
after 20 h incubation when compared with control cells (Fig.
1, C and D).
We have demonstrated previously that LL-37 was not lytic to
PMN [10]. Furthermore, no significant necrosis was observed
at 0, 1, 4, or 6 h (ref. [10], and data not shown). However,
significant (P0.001) induction of necrosis was observed at
12 h (data not shown) and thereafter, occurring at time-points
at which substantial apoptosis was observed. In keeping with
recent publications [38, 41], this suggested prior induction of
apoptosis may be necessary and that LL-37 might induce sec-
ondary necrosis. To confirm this in our model system, PMN
were exposed to early or late pulses of LL-37. PMN incubated
with LL-37 (5 g/ml) for 4 h, followed by washing and incu-
bation in control media for 16 h, had proportions of apopto-
tic, necrotic, and live cells identical to untreated controls (data
not shown). In contrast, 20 h incubation of cells in control
media, followed by exposure to LL-37 for just 10 min before
FACS analyses, completely replicated the dose-dependent ef-
fect of 20 h incubation with LL-37 (Fig. 1E), demonstrating
that LL-37 induced a rapid secondary necrosis of apoptotic
PMN without affecting live cells.
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Figure 1. Induction of PMN ne-
crosis by LL-37. (A–D) Freshly
isolated human PMN were incu-
bated for 20 h over a range of
LL-37 concentrations before
analyses. Primary necrosis was
induced by heating at 65°C for
30 min. Cell death was exam-
ined by FACS analyses and TEM
morphology. (A) Apoptotic
(FITC-AV-positive, PI-negative),
necrotic (FITC-AV-positive, PI-
positive), and live (FITC-AV-
negative, PI-negative) cells were
enumerated. Figures represent
mean values  sem for n  28
different donors for each condition, performed in triplicate. Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison
test comparing each treatment with control; **, P  0.01; ***, P  0.001. (B) Representative FACS plots. (C and D) Representative TEM images
of (C) untreated, apoptotic PMN and (D) PMN exposed to 5 g/ml LL-37. Arrows indicate examples of necrotic PMN. (E) Freshly isolated hu-
man PMN were incubated for 20 h over a range of LL-37 concentrations (20 h samples) or incubated for 20 h in the absence of LL-37 followed
by exposure to a range of LL-37 concentrations for 10 min (pulse samples) before FACS analyses of apoptotic, necrotic, and live cells. Panels rep-
resent mean values  sem for n  3 donors performed in triplicate. Significance was assessed by two-way ANOVA with Bonferroni’s post-test; **,
P  0.01; ***, P  0.001, compared with untreated control.
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Interaction of LL-37 with known modulators of PMN
apoptosis
To investigate whether LL-37 can interact with and modulate
the effects of known modifiers of PMN apoptosis pathways,
cells were incubated with LL-37 in the presence or absence of
GM-CSF (a PMN survival factor [42]) or R-Roscovitine (a cy-
clin-dependent kinase inhibitor and inducer of PMN apoptosis
[9]). GM-CSF reduced PMN apoptosis significantly at 20 h,
increasing the proportion of live cells with no effect on necro-
sis (Fig. 2A). Concomitant treatment with 5 g/ml LL-37 had
no effect on the capacity of GM-CSF to promote cell survival
but significantly (P0.05) increased the proportion of necrotic
cells with a reciprocal loss of apoptotic cells when compared
with GM-CSF alone (Fig. 2A). R-Roscovitine induced PMN apop-
tosis significantly at 6 h with minimal necrosis (Fig. 2B). LL-37
alone (25 g/ml) had no effect on cell death at this time-
point. Concomitant LL-37 treatment had no effect on the ca-
pacity of R-Roscovitine to induce cell death but significantly
(P0.01) increased the proportion of necrotic cells in a dose-
dependent manner with a reciprocal loss of apoptotic cells
when compared with R-Roscovitine alone (Fig. 2B). These data
demonstrate no interaction with these direct modifiers of PMN
apoptosis, but LL-37 induced secondary necrosis, relating in
magnitude to the extent of induction of apoptosis.
In addition, studies were performed to assess the impact of
LL-37 (a well-characterized antiendotoxic agent [15]) on the
antiapoptotic effects of LPS in PMN [43]. LPS promoted PMN
survival (Fig. 2C) significantly, inhibiting apoptosis without
inducing necrosis (Fig. 2D). Concomitant incubation with
LL-37 inhibited this effect significantly in a dose-dependent
manner. LL-37 (5 g/ml) blocked the pro-survival effects of
LPS completely and significantly increased the proportion of
dead cells that were necrotic (P0.01). However, the capacity
of 5 g/ml LL-37 to induce secondary necrosis was diminished
significantly by LPS (P0.001). These data demonstrate LL-37-
mediated inhibition of the antiapoptotic effects of LPS and
suggest a mutually inhibitory interaction with LPS diminishing
LL-37-induced secondary necrosis.
LL-37-mediated induction of secondary necrosis is
conserved in mCRAMP and C-terminal partial
peptides and is not primarily charge-dependent
To examine the important characteristics of LL-37 for the ca-
pacity to induce secondary necrosis, FACS-based studies were
performed using a scrambled LL-37 peptide (with conserved
charge but altered amino acid sequence), the murine homo-
logue mCRAMP, and a panel of sixteen 22-mer partial pep-
tides spanning the sequence of LL-37 [37]. Incubation of
PMN with scrambled LL-37 had no effect, whether exposed
over 20 h or as a final 10-min pulse (Fig. 3A). In contrast,
mCRAMP exposure closely replicated the effects of LL-37 with
significant, dose-dependent induction of secondary necrosis
(Fig. 3B). Exposure to N-terminal 22-mer partial LL-37 pep-
tides (from the peptide incorporating aa 1–22 of LL-37
through that spanning aa 10–31) had no significant effects
(Fig. 3C). In contrast, C-terminal partial peptides (from the
peptide incorporating aa 11–32 through that spanning aa 16–
37) induced significant secondary necrosis (P0.01) in the
absence of effects on live cells but to a lesser extent than full-
length LL-37. This identified a putative minimal core func-
tional region for induction of secondary necrosis spanning aa
16–32. The effects of these peptides showed no correlation
with charge, which ranged from 3 to 6. These data demon-
strate that the capacity to induce PMN secondary necrosis is
evolutionarily conserved between mouse and human cathelici-
din, is not primarily dependent on peptide charge, and is re-
tained by C-terminal but not N-terminal-truncated peptides of
LL-37.
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Figure 2. LL-37 exposure of PMN in the presence of modifiers of apoptotic pathways. Freshly
isolated human PMN were incubated with LL-37 (at the concentrations indicated) for 20 h in
the presence or absence of 20 ng/ml GM-CSF (A), for 6 h in the presence or absence of 20 M
R-Roscovitine (B), or for 20 h in the presence or absence of 500 ng/ml E. coli LPS (C and D).
Cell death was examined by FACS analyses. Figures represent mean values  sem for n  3 do-
nors performed in triplicate. Significance was assessed by one-way ANOVA with Bonferroni’s
multiple comparison test comparing each treatment with control; *, P  0.05; **, P  0.01, for
necrotic (A, B, and D) or viable (C) cells in LL-37-treated samples compared with controls with-
out LL-37 in the presence of (A) GM-CSF, (B) R-Roscovitine, or (C) LPS; #, P  0.001, for necrotic
(D) or viable (C) cells in LPS-treated samples compared with controls without LPS in the compara-
ble concentration of LL-37.
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LL-37-induced secondary necrosis of apoptotic PMN
does not inhibit macrophage efferocytosis
To determine whether macrophage ingestion of dead PMN
was altered by LL-37-mediated secondary necrosis, ingestion of
LL-37-treated PMN was studied using MDM by light micro-
scopic enumeration (Fig. 4A). Confirmatory studies were per-
formed using FACS analyses of MDM to determine ingestion
of labeled PMN (Fig. 4B). In both studies, positive control
dexamethasone-primed macrophages (shown previously to
have increased capacity for apoptotic PMN ingestion [40])
were used. LL-37-mediated induction of secondary necrosis
had no significant effects on the magnitude of PMN ingestion
by MDM, even at 25 g/ml LL-37 (a concentration at which
80% of dead cells are necrotic [10]).
LL-37-induced secondarily necrotic PMN do not
induce proinflammatory macrophage responses
The interaction of apoptotic PMN and macrophages can in-
duce anti-inflammatory macrophage responses and inhibit
LPS-induced proinflammatory cytokine responses [5]. In con-
trast, necrotic cells are suggested to induce proinflammatory
responses [44]. To examine the effects of LL-37-mediated
PMN secondary necrosis, MDM cytokine responses to these
cells were evaluated at 18 h after exposure. To separate the
effects of any residual, functional LL-37 in the media from the
effects of the dead PMN and of the cell bodies from the cellu-
lar contents released from secondarily necrotic cells, PMN
were incubated for 20 h at a range of concentrations of LL-37,
and MDM were then exposed to LL-37-treated PMN, resus-
pended in fresh serum-free media, unwashed LL-37-treated
PMN in their original media, supernatant from LL-37-treated
PMN alone, or media without PMN as a control.
MDM exposed to control apoptotic PMN, PMN incubated
for 20 h with LL-37 (25 g/ml), or the supernatants from
these cells did not produce detectable levels of TNF-, IL-6,
IL-10, IL-12p70, or IL-1 (Fig. 5, and data not shown), and
there were no significant differences between responses to LL-
37-treated and control apoptotic PMN. These data suggest that
LL-37-induced secondarily necrotic PMN are not proinflamma-
tory to macrophages nor release effective, proinflammatory
contents into the supernatant.
LL-37-induced secondarily necrotic PMN have anti-
inflammatory effects on macrophages
To determine the effect of these cells in the context of proin-
flammatory stimuli, MDM were exposed concomitantly to 10
ng/ml E. coli LPS. Treatment of MDM with LPS alone stimu-
lated significant production of TNF-, IL-6, and IL-10 (but not
IL-12p70 or IL-1). In keeping with previous reports [5], the
LPS-induced proinflammatory response was reduced by the
addition of control apoptotic PMN in serum-free media with
significant inhibition (P0.01) of TNF- and IL-6 (Fig. 6A).
However, these control apoptotic cells had no significant effect
on LPS-induced IL-10 production (with considerable donor
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Figure 3. Peptide specificity in the
induction of PMN secondary ne-
crosis. Freshly isolated human
PMN were incubated with (A) a
range of concentrations of scram-
bled LL-37 peptide for 20 h, or
for 10 min after 20 h incubation
in the absence of peptide (pulse);
n  3 donors performed in tripli-
cate; (B) a range of concentra-
tions of mCRAMP peptide; n 
16 donors performed in tripli-
cate; or (C) 5 g/ml partial
LL-37 peptides from a panel of
16 overlapping 22-mers using N-
terminal peptide (aa 1–22), then
peptide spanning aa 2–23, and so
on through C-terminal peptide
(aa 16–37) or full-length LL-37;
n  3 donors performed in tripli-
cate. Peptides p1, p2, and p3 are
identified. Cell death was exam-
ined by FACS analyses as de-
scribed. Figures represent mean
values  sem. Significance was
assessed by one-way ANOVA with
Bonferroni’s multiple comparison
test comparing each treatment
with control; **, P  0.01; ***,
P  0.001.
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variation). Contrary to expectation, when PMN, incubated pre-
viously for 20 h with LL-37 to induce secondary necrosis, were
resuspended in fresh, serum-free media and used, these cells
also inhibited LPS-induced TNF- and IL-6 responses. The ef-
fect of cells incubated previously with 5 g/ml LL-37 to in-
duce secondary necrosis was not significantly different than
control apoptotic cells (Fig. 6A). However, significantly greater
inhibition of LPS-induced TNF- (P0.01) was observed in
response to cells incubated previously with 25 g/ml LL-37
(Fig. 6A), in which the largest induction of secondary necrosis
is evident. In addition, in contrast to control apoptotic cells, a
trend toward diminished, LPS-induced MDM IL-10 responses
was observed in response to these secondarily necrotic cells
(Fig. 6A). Exposure of MDM to control apoptotic PMN in
their original supernatant (Fig. 6B) had no effect on the LPS-
induced production of TNF-, IL-6, or IL-10 by MDM and was
essentially the same as exposure to the supernatant alone
(data not shown). In contrast, exposure to unwashed, LL-37-
treated PMN in their original supernatant did inhibit the LPS-
induced production of TNF- (P0.001), IL-6 (P0.05), and
IL-10 by MDM (Fig. 6B). This effect could be replicated using
supernatants alone (data not shown) but was not observed us-
ing cells treated with scrambled LL-37 (Fig. 6B). In addition,
fresh LL-37, added directly to LPS-stimulated MDM in the ab-
sence of PMN, was able to replicate this inhibitory effect (Fig.
6B), indicating that the antiendotoxic effects of remaining,
active LL-37 in the original supernatant may be responsible for
the results observed in these latter studies. To determine
whether the loss of inhibitory activity of dead PMN in their
original supernatant related to cellular products or serum
within the original media, 20 h PMN, washed and resuspended
in fresh serum-containing media, were used. These cells (con-
trol and LL-37-treated) lost the capacity to inhibit LPS-induced
MDM TNF- production (Fig. 7A), implicating an unidentified
serum-factor and demonstrating that washed, LL-37-treated cells
did not have sufficient residual LL-37 to be directly antiendo-
toxic.
To confirm that the anti-inflammatory effects of LL-37-in-
duced secondarily necrotic PMN were independent of the anti-
endotoxic effects of the peptide, rCD40L and rIFN- treat-
ment was used to activate MDM, rather than LPS. Control-
apoptotic and LL-37-induced secondarily necrotic PMN were
capable of significantly (P0.001) inhibiting the resultant
TNF- production (Fig. 7B).
In addition, the impact of three 22-mer partial LL-37 pep-
tides was evaluated. N-terminal peptide p1 induced no PMN
secondary necrosis (Fig. 3C) and had no direct antiendotoxic
effects when applied to LPS-treated MDM (Fig. 7C). C-termi-
nal peptides p2 and p3 induced significant PMN secondary
necrosis (Fig. 3C), but whereas p2 had direct, significant anti-
endotoxic effects (P0.05), p3 did not (Fig. 7C). When PMN,
incubated previously for 20 h with these peptides, were resus-
pended in fresh serum-free media, these cells were all capable
of mediating a significant (P0.01) inhibition of LPS-induced
MDM TNF- production, identical to control cells (Fig. 7D).
However, when used in their original media, the effects of
these cells replicated the direct, antiendotoxic capacity of the
peptide with which they had been treated (Fig. 7C).
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Figure 4. Macrophage phagocytosis of LL-37-induced secondarily ne-
crotic PMN. PMN were incubated previously for 20 h, with or without
LL-37 (or scrambled LL-37) at the stated concentrations, and then
incubated with hMDM for 1 h before removal of noningested PMN.
Phagocytosis was assessed by (A) light microscopy, counting the pro-
portion of MDM peroxidase-positive cells; n  3 donors for each con-
dition and n  2 replicates/experiment; or (B) flow cytometric analy-
ses, evaluating the proportion of MDM ingesting Cell Tracker Green-
stained PMN; n  3 donors for each condition, with n  2 replicates/
experiment. As a positive control, wells of adherent monocytes were
also cultured in the presence of 1 M dexamethasone for 5 days to
up-regulate MDM phagocytosis of dead PMN. Significance was assessed
by one-way ANOVA with Bonferroni’s multiple comparison test com-
paring each treatment with control; *, P  0.05; **, P  0.01.
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Figure 5. LL-37-induced second-
arily necrotic PMN are not proin-
flammatory for macrophages. Hu-
man PMN were incubated for 20 h
in the presence or absence of
LL-37 or scrambled LL-37 at the
concentrations indicated and used
unwashed in the IMDM  10% FCS
media supernatant, in which they
had been incubated. hMDM were
incubated with these PMN or incu-
bated without PMN (nc) in the pres-
ence or absence of LL-37 or 10
ng/ml E. coli 0111:B4 LPS as a posi-
tive control. Supernatants were eval-
uated for cytokine responses.
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These data demonstrate the effect of residual peptide in the
original media, show that functional peptide is not carried
over in washed cells, and demonstrate that these dead PMN
can inhibit LPS-induced MDM cytokine production, irrespec-
tive of the degree of peptide-induced secondary necrosis. These
data demonstrate that the inhibition of activated MDM proin-
flammatory cytokine production mediated by apoptotic PMN is
not inhibited and may even be enhanced by LL-37-mediated
induction of secondary necrosis of these apoptotic PMN.
Furthermore, the intracellular contents released by these
cells are not actively proinflammatory or can be inhibited
by the effects of LL-37.
LL-37-mediated secondary necrosis can induce the
release of PMN granule contents
To determine the effect of LL-37-induced secondary necrosis
of apoptotic PMN on the azurophilic (primary) granules, the
release of MPO in response to LL-37 was quantified at 20 h.
MPO release was not detected above background for this time-
point following exposure to 10 g/ml LL-37 (concentrations
at which substantial secondary necrosis occurred) or in re-
sponse to scrambled LL-37 (Fig. 8). However, significant levels
of MPO were observed in response to 25 g/ml LL-37
(P0.01) at levels approaching 40% of total MPO released by
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Figure 7. The anti-inflammatory properties LL-37-induced, secondarily necrotic PMN are independent of peptide antiendotoxic activity. Human
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resuspended in X-vivo 10 media with 10% FCS (A), resuspended in serum-free X-vivo 10 media (B and D), or used unwashed in the IMDM 
10% FCS media supernatant, in which they were incubated overnight (C). MDM were incubated with these PMN, with concomitant exposure to
10 ng/ml E. coli 0111:B4 LPS (A, C, and D) or 3 g/ml rhCD40L  5 ng/ml rhIFN- (B) for 18 h. Activated MDM without PMN, in the presence
or absence of peptides, were also studied as controls and to evaluate direct antiendotoxic activity. Supernatants were evaluated for cytokine re-
sponses. Significance was assessed by one-way ANOVA with Bonferroni’s multiple comparison test; n  3 donors; *, P  0.05; **, P  0.01; ***,
P  0.001, compared with activated MDM in the absence of PMN under the same conditions.
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Figure 6. LL-37-induced secondarily ne-
crotic PMN retain anti-inflammatory prop-
erties. Human PMN were incubated for
20 h in the presence or absence of LL-37
or scrambled LL-37 at the concentrations
indicated. PMN were resuspended in se-
rum-free X-vivo 10 media (A) or used un-
washed in the IMDM  10% FCS media
supernatant, in which they were incubated
overnight (B). MDM were incubated with
these PMN, with concomitant exposure to
10 ng/ml E. coli 0111:B4 LPS for 18 h. LPS-
treated MDM without PMN, in the pres-
ence or absence of LL-37, were also studied
as controls. Supernatants were evaluated for
cytokine responses. Significance was as-
sessed by one-way ANOVA with Bonferro-
ni’s multiple comparison test; n  9 donors
(TNF-); n  5 donors (IL-6/IL-10); *, P 
0.05; **, P  0.01; ***, P  0.001, com-
pared with MDM exposed to LPS in the
absence of PMN under the same condi-
tions; ##, P  0.01; ###, P  0.001, com-
pared with MDM exposed to control apo-
ptotic PMN untreated with LL-37.
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lysis with Triton X-100. These data suggest that although LL-
37-induced secondary necrosis of apoptotic PMN does not lead
directly to the release of granule contents over this time scale,
higher concentrations of LL-37 are able to destabilize granules
and lead to the release of their potentially damaging contents.
DISCUSSION
PMN are key cells of the innate immune system. The appropri-
ate regulation of PMN function, death, and clearance is criti-
cal to effective control of inflammation, and dysregulation of
these processes has been implicated in disease pathogenesis.
Cell death by apoptosis, followed by efferocytosis by profes-
sional phagocytic cells, is proposed to enable safe PMN re-
moval without the release of harmful intracellular contents to
inhibit proinflammatory responses and to promote anti-inflam-
matory responses to enhance resolution [3]. In contrast, cell
death by necrosis (whether primary necrosis or secondary ne-
crosis of apoptotic PMN that have not been cleared) is pro-
posed to be proinflammatory. We demonstrate that the human
cathelicidin LL-37 is a potent inducer of secondary necrosis in
PMN, which have undergone prior apoptosis, and evaluate the
impact of this process on macrophage inflammatory responses.
We demonstrate that the ingestion of LL-37-induced second-
arily necrotic PMN was not a proinflammatory event. This pro-
cess did not promote the release of proinflammatory cytokines
by macrophages and was indistinguishable from the macro-
phage response to apoptotic cells. Furthermore, these second-
arily necrotic PMN were actively anti-inflammatory, demon-
strating that the capacity of apoptotic PMN to inhibit LPS-in-
duced proinflammatory cytokine production by macrophages
was undiminished by LL-37-induced secondary necrosis. In-
deed, this anti-inflammatory effect was actually enhanced in
response to PMN with the most extensive secondary necrosis.
Although the anti-inflammatory activity of unwashed, LL-37-
treated apoptotic PMN was a result of the antiendotoxic prop-
erties of the remaining, functional LL-37 in the supernatant,
washed cells retained the anti-inflammatory capacity of control
apoptotic cells, even after treatment conditions (25 g/ml
LL-37 for 20 h) in which 80% of dead PMN have undergone
secondary necrosis [10]. These data suggest functional equiva-
lence, irrespective of membrane integrity, of apoptotic PMN
and LL-37-induced secondarily necrotic cells in this system. A
previous report has demonstrated potential functional domi-
nance of apoptotic cells over primary necrotic cells [45]. We
cannot exclude a dominant role for the remaining membrane-
intact apoptotic cells in our system. However, the significantly
enhanced anti-inflammatory effects induced by PMN, with the
greatest proportion of secondary necrosis, indicate that the
anti-inflammatory activity of apoptotic PMN can in fact be po-
tentiated by LL-37-induced secondary necrosis. Whether this
applies to PMN necrosis induced in other ways and the mecha-
nisms involved remains to be determined. However, exposure
to a concentration of LL-37, sufficient to induce PMN granule
content release, appeared to be necessary to generate second-
ary necrosis capable of potentiating the anti-inflammatory ef-
fects. This indicates that induction of necrosis per se is not
sufficient and implicates a possible role for the release of en-
dogenous LL-37 or other anti-inflammatory agents from PMN
granules. Irrespective, it is clear that LL-37-induced secondary
necrosis did not compromise the anti-inflammatory effects of
the dead cells nor confer proinflammatory properties on
them. Furthermore, any proinflammatory mediators released
by secondarily necrotic PMN into the supernatant were unable
to initiate or potentiate macrophage production of the cyto-
kines studied in the presence of LL-37.
Whereas apoptosis has been viewed as anti-inflammatory and
inducing immune-tolerance, necrosis has been considered a
proinflammatory and immunogenic form of cell death. How-
ever, recent studies have suggested that this axiom is oversim-
plified [46]. Apoptotic Jurkat T cells are reported to be
equally potent in modulating macrophage MAPK pathways,
irrespective of membrane integrity [47], and the membranes
of apoptotic and primary necrotic PMN have been shown to
inhibit TNF- production by activated macrophages [44]. In
addition, apoptosis can neutralize potential intracellular dan-
ger signals, such as high-mobility group box-1 protein, via
caspase-activated mitochondrial reactive oxygen species pro-
duction [48]. Thus, the release of intracellular contents from
apoptotic cells having undergone secondary necrosis may not
be equivalent to the proinflammatory contents of primary ne-
crotic cells, an hypothesis that would be compatible with our
data.
We demonstrate that LL-37-induced PMN secondary necro-
sis had no impact on the magnitude of ingestion of dead PMN
by macrophages, consistent with previous reports [44, 45]. Ef-
ferocytosis is a complex process with multiple receptors and
adaptors proposed [3], independent from the anti-inflamma-
tory effects initiated by apoptotic cells [49]. We cannot ex-
clude the possibility that the mechanism of ingestion of these
secondary necrotic PMN and apoptotic PMN may be different,
but comparable levels of uptake suggest that LL-37-mediated
induction of PMN secondary necrosis in vivo would not inhibit
the clearance of dead PMN.
Irrespective of the impact of secondary necrosis on the
clearance of dead PMN or macrophage cytokine responses,
the loss of PMN membrane integrity presents the additional
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Figure 8. LL-37-induced secondary necrosis of PMN can release gran-
ule contents. Isolated human PMN were incubated for 20 h with a
range of concentrations of LL-37 or 50 g/ml scrambled LL-37
(sc50). The concentration of MPO in the supernatants was evaluated
as a percentage of total MPO release after lysis of fresh control PMN
using 0.1% Triton X-100. Significance was assessed by one-way ANOVA
with Bonferroni’s multiple comparison test; n  7 donors; **, P 
0.01, compared with untreated PMN.
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threat of the release of harmful intracellular contents, includ-
ing granule contents such as neutrophil elastase, cathepsin G,
MPO, and gelatinase [50]. In contrast to previous TEM-based
observations [38], our data demonstrate that high concentra-
tions of LL-37 induced the release of MPO from the azuro-
philic granules. Interestingly, this was not observed at lower
LL-37 concentrations, at which significant induction of second-
ary necrosis was observed nevertheless. This suggests that LL-
37-induced secondary necrosis did not disrupt granule integ-
rity per se but that high concentrations of LL-37 (10 g/ml)
had the capacity to damage granule membranes in addition to
apoptotic outer membranes. The consequences of such an ef-
fect in a rapidly resolving acute infection may contrast with
those in a chronic inflammatory process associated with high
levels of LL-37. Indeed, increased hCAP-18/LL-37 concentra-
tions in cystic fibrosis lung disease (detected at up to 15
g/ml in BALF from patients without recent infectious exacer-
bation) were correlated with increased lung damage [34], and
raised pulmonary LL-37 levels are associated with bronchiolitis
obliterans syndrome in the recipients of lung transplants [36].
In addition, LL-37 has been proposed recently to contribute to
the pathogenesis of psoriasis [35], and the concentration of
hCAP-18/LL-37 was reported to be 1.5 mg/ml in psoriatic
skin lesions [51]. These estimates of in vivo peptide concentra-
tions do not take into account the recent observation that the
ratio of active LL-37 to full-length precursor hCAP-18 varied
considerably between donors in the inflamed lung [36]. Nev-
ertheless, at these concentrations, extensive induction of sec-
ondary necrosis of apoptotic PMN, with the release of PMN
granule contents, could be generated by exposure to LL-37 in
vivo. Thus, the potentially detrimental effects of LL-37-medi-
ated induction of PMN secondary necrosis could have signifi-
cance in chronic disease processes.
The potential consequences of PMN granule release may be
of particular significance for the ongoing development of
CHDP as therapeutic agents for infectious and inflammatory
diseases. A greater knowledge of the capacity of these peptides
to modulate inflammation and the peptide attributes that con-
fer them will have important implications. We have demon-
strated recently that the capacity of LL-37 to induce secondary
necrosis of apoptotic cells is not specific to PMN [41] and now
additionally define a core functional region and describe inter-
action with other modifiers of cell death.
We demonstrate that LL-37-induced secondary necrosis of
PMN occurred rapidly, within minutes of exposure of an apop-
totic PMN to the peptide. The specific membrane alterations
that make these apoptotic cells acutely susceptible to damage
by LL-37 and the nature of this interaction remain unclear,
but the process has been proposed recently to be energy-inde-
pendent [38] and independent of known LL-37 receptors
[41]. Our data demonstrate that this property was conserved
in the murine ortholog mCRAMP, and the effect was not de-
pendent primarily on peptide charge (with no effects seen for
a scrambled sequence peptide with the same charge) and was
retained partially by C-terminal, but not N-terminal partial
LL-37 peptides. These latter studies, using truncated partial
peptides, shown previously to be poorly antiendotoxic [37],
identified a minimal core-functional region for induction of
secondary necrosis by LL-37, spanning aa 16–32. This may in-
dicate an important motif or be related to the more amphi-
pathic nature of the peptides spanning this region. Interest-
ingly, the region 17–32 has been identified previously as the
core antimicrobial region [52]. This suggests a possible conser-
vation of mechanism between the direct microbicidal effects of
LL-37, for which amphipathicity is critical [52], and the capac-
ity to induce PMN secondary necrosis. However, it is notewor-
thy that whereas core LL-37 peptide 17-32 had enhanced mi-
crobicidal function compared with full-length LL-37, our par-
tial peptides had diminished capacity to induce secondary
necrosis. This has important implications for the development
of therapeutic peptides and in consideration of the possible in
vivo activities of shorter-form cleavage products of hCAP-18,
identified previously in the skin [53]. Further study of our par-
tial peptides will enable dissection of the various properties of
LL-37.
In conclusion, we demonstrate that the human cathelicidin
LL-37 is a potent inducer of secondary necrosis of apoptotic
PMN, with the potential to alter the profile of PMN cell death
at sites of infection and inflammation. Our data give novel in-
sights into the potential effects of PMN secondary necrosis,
suggesting that LL-37-mediated secondary necrosis of PMN
does not have proinflammatory effects on macrophages and
can even potentiate the anti-inflammatory effects of efferocyto-
sis. These data challenge the prevailing model that although
apoptotic cells are anti-inflammatory to macrophages, necrotic
cells (whether primary or secondary necrosis) are inherently
proinflammatory. This has particular importance for the de-
layed clearance of the apoptotic cell hypothesis for chronic
inflammation and implications for novel, anti-inflammatory
strategies being developed based on our understanding the
mechanisms controlling the resolution of inflammation. How-
ever, we also demonstrate that LL-37-induced secondary necro-
sis has the potential to induce the release of potentially harm-
ful granule contents, which could have deleterious conse-
quences for the host, particularly in chronic disease states. We
demonstrate that this induction of secondary necrosis by LL-37
is not primarily charge-dependent, is partially retained by C-
terminal partial peptides, and is conserved in the murine or-
tholog. Further understanding of this mechanism and its phys-
iological significance will assist the appropriate modification of
synthetic analogs as novel therapeutics, illuminate possible
roles in the pathogenesis of chronic disease, and advance our
understanding of the impact of different cell death processes
in the promotion and resolution of inflammation.
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